Tag: BEYFORTUS®

Clinical Trials Healthcare & Pharmaceuticals News

New Study Shows 87% Reduction in RSV-Related Doctor Visits for Infants Treated with Sanofi’s BEYFORTUS®

sanofi

A groundbreaking real-world study has revealed that Beyfortus (nirsevimab-alip) significantly reduces the incidence of respiratory syncytial virus (RSV) disease in infants. The largest of its kind in the United States, the study demonstrated an 87% reduction in RSV cases requiring a visit to a doctor or hospital and a 98% decrease in hospitalizations among infants who received the treatment.

Supply Chain Healthcare & Pharmaceuticals News

Sanofi Accelerates Global Shipping of BEYFORTUS® Ahead of 2025–2026 RSV Season

sanofi

Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA [Read More…]